ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,Y
2,2,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
3,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
3,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
3,3,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
6,1,Tracheostomy,Tracheal therapeutic procedures,Respiratory tract therapeutic procedures,Surg,N
7,1,Activated partial thromboplastin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
7,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
7,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
8,1,Sinus bradycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
9,1,Sinus bradycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
10,1,Lung adenocarcinoma,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
10,2,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
10,3,Vena cava thrombosis,Vena caval embolism and thrombosis,Embolism and thrombosis,Vasc,N
11,1,Atrial septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
12,1,Atrial septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
13,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
14,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
14,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
14,3,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
14,4,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
14,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
15,1,Extravasation blood,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
15,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
16,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
17,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
18,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
